Ultromics designed EchoGo Amyloidosis to evaluate routine echocardiogram results for signs of cardiac amyloidosis. It received the FDA's breakthrough device designation back in 2023.
A new analysis in JACR estimates that spotting the signs of a previously undetected stroke could benefit up to 200,000 people in the United States every year.
By expediting communication between radiologists and referring providers when suspicious findings are identified, the system has great potential to improve clinical outcomes in real-world scenarios, authors of a new study in JACR suggest.
A recent analysis of an already CE-marked, AI-based system that identifies pneumothorax on chest radiographs revealed a weak point in what has largely been considered a reliable support tool.
A recent analysis of an already CE-marked, AI-based system that identifies pneumothorax on chest radiographs revealed a weak point in what has largely been considered a reliable support tool.
The software is the first of its kind to achieve the FDA's approval for detecting, measuring and grading ARIA on MRI scans—a task that is critical in managing the disease.
Ultromics designed EchoGo Amyloidosis to evaluate routine echocardiogram results for signs of cardiac amyloidosis. It received the FDA's breakthrough device designation back in 2023.
The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.
FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
